Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02017639 · ClinicalTrials.gov registry record · Phase 1
Sarilumab Effect on the Pharmacokinetics of Simvastatin
A Phase 1 study, sponsored by Sanofi.
- Completed
- Registry status
- Phase 1
- Development phase
- 19
- Enrollment target
NCT02017639 is a Phase 1 study that has completed, run by Sanofi. The registered enrollment target is 19 participants.
The verdict
NCT02017639, a Phase 1 study, has completed, sponsored by Sanofi.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 19 participants
- Enrollment target
Study Summary
Primary Objective: To evaluate the effect of a single 200 mg subcutaneous injection of sarilumab on the pharmacokinetics of simvastatin in patients with rheumatoid arthritis Secondary Objective: To describe the safety and efficacy (exploratory) of sarilumab
Interventions
- DRUG simvastatin
- DRUG sarilumab SAR153191 (REGN88)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 19 participants |
| Start Date | 2014-01 |
| Est. Completion | 2016-03 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02017639
The ClinicalTrials.gov registry entry for NCT02017639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which simvastatin is the first listed.
NCT02017639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02017639 about?
NCT02017639 is a clinical study titled "Sarilumab Effect on the Pharmacokinetics of Simvastatin". Primary Objective: To evaluate the effect of a single 200 mg subcutaneous injection of sarilumab on the pharmacokinetics of simvastatin in patients with rheumatoid arthritis Secondary Objective: To describe the safety and efficacy (exploratory) of sarilumab
What is the current status of trial NCT02017639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2014-01. Estimated completion is 2016-03.
What interventions are being tested in trial NCT02017639?
The interventions under investigation include: simvastatin (DRUG), sarilumab SAR153191 (REGN88) (DRUG).
Who is sponsoring clinical trial NCT02017639?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.